Mecwins said the technology will be most suitable for hospital labs because it will enable hundreds of samples to be tested each day. However, the company has inked an agreement with San Diego-based healthcare diagnostics firm Quidel to enable use in doctor’s offices and other decentralized settings.
The technology, called Avac, can potentially detect multiple protein, RNA and DNA biomarkers on a single platform at high levels of sensitivity, Virginia Cebrián, PhD, Mecwin’s head of bioscience, told diagnostic tech news outlet 360Dx.
Ms. Cebrián said the firm has tested biomarkers including troponin I, a biomarker of myocardial infarction; prostate-specific antigens to detect prostate cancer recurrence after a prostatectomy; p24 to detect HIV; and cytokines to detect inflammation.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.